How This List Works
Every peptide below is ranked within its goal category by evidence strength — not by popularity, not by vendor availability, and not by social media buzz. Each entry shows its evidence level, what the research actually demonstrates, and where to learn more. This is the hub page that connects to the deep-dive articles.
Evidence key: FDA Approved = full clinical trials, FDA-approved for at least one indication. Strong = multiple controlled studies, well-characterized. Emerging = animal data + early human studies. Investigational = clinical trials ongoing, not available commercially.
Dual GLP-1/GIP agonist. ~20–22% average weight loss. The most effective FDA-approved option. Weekly injection. Works through appetite reduction, insulin sensitization, and slowed gastric emptying.
GLP-1 agonist. ~15–17% average weight loss. Most widely prescribed and studied. Weekly injection. Longest real-world track record of the new-generation GLP-1s.
Non-peptide GLP-1 oral pill. ~12.4% weight loss. No food, water, or timing restrictions. Best option for women who won't inject or can't follow the oral semaglutide fasting protocol. ~$149/mo self-pay.
Triple agonist (GLP-1 + GIP + glucagon). 28.3% average loss in Phase 3 with no plateau at 104 weeks. Not yet approved — NDA filing expected Q4 2026. The glucagon component may preferentially target visceral fat. Read the full review for the 20.9% dysesthesia signal.
Deep dive: Retatrutide for Women · Foundayo Review · Muscle Loss on GLP-1s · GLP-1 Dosing for Women
Copper-binding tripeptide. Stimulates collagen synthesis, fibroblast activation, hyaluronic acid production, and antioxidant enzymes. Decades of topical data. Especially relevant for menopause-related collagen decline (~30% loss in first 5 years). Available as serum or injectable.
Tetrapeptide studied for telomere support and pineal gland regulation. The anti-aging case is theoretical — limited clinical data exists. Mostly of interest for the longevity-focused.
Deep dive: Menopause, Collagen Loss, and GHK-Cu · GHK-Cu for Female Hair Loss
Gastric pentadecapeptide with broad anti-inflammatory and tissue-repair properties. Dozens of animal studies showing gut-barrier protection, mucosal healing, and anti-inflammatory effects. A pilot study in interstitial cystitis showed results in 10/12 women. IBS affects women at 2× the rate of men — making this especially relevant.
Anti-inflammatory tripeptide derived from alpha-MSH. Suppresses NF-kB signaling — the central inflammatory pathway. Gut-specific evidence in colitis models. Complementary to BPC-157 (different mechanisms).
Triggers ovulation via the natural HPG axis without OHSS risk. Clinical trial data from Imperial College London. Especially relevant for PMOS. Not yet available commercially — kisspeptin-10 from vendors is a truncated form, not the kisspeptin-54 used in trials.
Not a fertility drug — but improving insulin sensitivity with GLP-1 agonists can restore ovulatory function in PMOS-related anovulation. The "Ozempic baby" phenomenon is real. Requires washout before planned pregnancy.
Deep dive: Kisspeptin and Ovulation · Peptides and Fertility: Hype vs Evidence · The Ozempic Baby Phenomenon
Anxiolytic peptide approved in Russia. Modulates GABA, increases BDNF, and influences enkephalin — without sedation or dependence. Nasal spray delivery. Anxiety affects women at 2× the rate of men. Not FDA-approved; limited Western clinical data.
Promotes delta-wave sleep without sedative hangover. Research dates to the 1970s–80s. Often paired with Selank in the peptide community for combined mood and sleep support.
The only FDA-approved peptide for hypoactive sexual desire disorder (HSDD) in premenopausal women. Works through melanocortin receptors in the brain — not hormones or blood flow. On-demand injection. Main side effect: nausea (~40%).
Deep dive: Peptides and Libido: What Works, What's Snake Oil
Target insulin resistance — the primary metabolic driver of PMOS. Improve HOMA-IR, reduce androgen levels, increase SHBG, promote weight loss, and can restore ovulatory cycles. Not FDA-approved specifically for PMOS but increasingly prescribed for it.
Mitochondrial-derived peptide activating AMPK (the same metabolic sensor metformin targets). Improves insulin sensitivity and glucose metabolism. Being reviewed by the FDA PCAC. Much smaller evidence base than GLP-1 agonists.
Deep dive: The 4 Root Dysfunctions Behind PMOS · GLP-1s for PMOS · PCOS Is Now PMOS
The Quiz Shortcut
Not sure which goal is your starting point? The FemPeptides Peptide Finder Quiz walks you through 5 questions — life stage, primary goal, specific concern, experience level, and administration preference — and recommends 1–3 peptides ranked by relevance. Every recommendation links to the full profile page with evidence ratings and vendor options.
Frequently Asked Questions
What is the best peptide for women's weight loss?
Tirzepatide (Zepbound) is the most effective approved option (~20–22% loss). Semaglutide (Wegovy) is the most widely used (~15–17%). Orforglipron (Foundayo) is the best pill (~12.4%, no restrictions). Retatrutide (28.3%) is investigational.
What is the best peptide for women's skin and anti-aging?
GHK-Cu — decades of data on collagen synthesis, elasticity, and skin density. Especially relevant for menopausal skin changes. Available as topical serum (most studied for facial skin) or injectable.
What peptides help with women's gut health?
BPC-157 (strongest preclinical gut-healing evidence) and KPV (targeted anti-inflammatory). IBS affects women at 2× the rate of men. Neither has completed large-scale human clinical trials for gut conditions.